Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)

University of Illinois at Chicago · with Eli Lilly and Company · NCT07408531

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 50–80 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
2500
US sites recruiting
2
Study start
March 12, 2026
Record last updated
August 6, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This research study aims to investigate methods for enhancing lung cancer screening. The study will investigate whether an artificial intelligence (AI) tool, known as Sybil, can aid in predicting the risk of lung cancer. The investigators will also examine whether expanding the screening criteria (based on the guidelines of the Potter and American Cancer Society (ACS)) can help identify individuals at risk who are not currently included in the U.S. Preventive Services Task Force (USPSTF) guidelines.

Being studied: Sybil Artificial Intelligence (AI) screening

Conditions: Lung Cancer Screening

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age 50-80 years at the time of consent
  • Meets at least one of the following LCS eligibility criteria:
  • USPSTF: ≥20 pack-years, currently smoke or quit ≤15 years ago.
  • Potter: 20 years of smoking, regardless of intensity
  • ACS: ≥20 pack-years, no restriction on quit time
  • Receiving or scheduled for LDCT through the UI Health Lung Screening Program.
  • Willing to view a short (approximately 2-minute) educational video that explains Sybil AI scoring and LCS, complete the Sybil AI survey (if selected), and/or provide blood samples (optional).
  • Able to provide written informed consent and HIPAA authorization for release of personal health information, via an approved UIC IRB ICF and HIPAA authorization.
  • Women of childbearing potential must not be pregnant or breastfeeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.
  • As determined at the discretion of the enrolling physician or protocol designee, the ability of the subject to understand and comply with study procedures for the entire length of the study

Exclusion Criteria

  • Inability to undergo LDCT
  • Current diagnosis or history of lung cancer \< 5 years prior to study enrollment.
  • Life expectancy \<1 year
  • Active lung infection requiring systemic therapy
  • Vulnerable population, including prisoners and pregnant or nursing women, will not be enrolled due to radiation exposure from LDCT, which is contraindicated in pregnancy.
  • Other major comorbidity, as determined by the study PI
  • Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial.

Recruiting US locations

  • UI Health

    Chicago, IL 60612

    Site contact: Mary Pasquinelli, DNP · 312-996-8039 · Mpasqu3@uic.edu

  • UI Health 55th and Pulaski Health Collaborative

    Chicago, IL 60629

    Site contact: Mary Pasquinelli, DNP · 312-996-8039 · Mpasqu3@uic.edu

Study contacts (from the official record)

  • Mary Pasquinelli, DNP · (312) 996-8039 · Mpasqu3@uic.edu
LUNG-07: Advancing Precision-Based Lung Cancer Screening:… (NCT07408531) | Bored Studies